Stephan Emmerth

Stephan Emmerth

PhD | Director Therapeutic Innovation and BaseLaunch

Tel. +41 61 295 50 17

report Life Sciences
(img: lab/pixabay)

(img: lab/pixabay)


Idorsia enjoys successful launch

The pharmaceutical research company Idorsia has enjoyed a successful launch following its demerger from Actelion. Its first drug candidates have already welcomed positive results.

Idorsia was founded by a demerger following Actelion’s acquisition by Johnson & Johnson and started operational business on 15th June. The company has now published its first half-year results, which refer to the period from the middle to the end of June.  

"We launched Idorsia on 15 June 2017 with a fully operational research and development engine and CHF 1 billion in cash. For the shortened financial year of 2017, we expect our non-GAAP operating expenses to be between CHF 180-190 million," said chief financial officer, Andre C. Müller, of the results.

In the research field, Idorsia achieved positive results for two drug candidates. The company conducted a phase 2 dose-finding results trial with aprocitentan, which was developed to treat resistant hypertension and will now move into phase 3 development.

The dual orexin receptor antagonist (DORA) ACT-541468 also achieved positive results in a phase 2 trial in insomnia. This drug will also now enter a phase 3 trial.

"I am very pleased and proud that we are fully functional after the successful demerger from Actelion. Innovation is and will always be the key to our success,” commented CEO Jean-Paul Clozel.


Life Sciences
Cookies uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.